EE637 Assessment of Clinically Meaningful Benefits and Incremental Costs of Adding Bevacizumab to Trifluridine/Tipiracil for Metastatic Colorectal Cancer: A Comparison With Other Combination Regimens
Abstract
Authors
R Epstein T Salimi N Khan L Abramovitz R Bornheimer D Weycker C Cann